{"id":"W4327560927","doi":"10.1136/jitc-2022-005301","title":"First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":63,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; GlaxoSmithKline","keywords":"Medicine; Pembrolizumab; Internal medicine; FOXP3; Pharmacodynamics; Tolerability; Adverse effect; Granzyme; Gastroenterology; Pharmacokinetics; Immunology; Pharmacology; CD8; Oncology; Immunotherapy; Immune system; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001702572,0.002073664,0.001984626,0.0004138454,0.0004666736,0.001014662,0.0009423395,0.001068608,0.004314214],"category_scores_gemma":[0.0007583556,0.0007270389,0.001066886,0.000456325,0.0009720775,0.001043734,0.0004476767,0.003609744,0.000977126],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001027465,"about_ca_system_score_gemma":0.001566441,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005717477,"about_ca_topic_score_gemma":0.0017789,"domain_scores_codex":[0.9995233,0.0002010975,0.00002221079,0.00008672867,0.00005487496,0.000111836],"domain_scores_gemma":[0.999319,0.0000960515,0.0001665839,0.00007178074,0.0000420413,0.0003046234],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6082342,0.1568949,0.006886568,0.001344371,0.001321476,0.0004668233,0.0005697531,0.002685001,0.1189349,0.0003947893,0.004798552,0.09746875],"study_design_scores_gemma":[0.3376296,0.6413931,0.007843267,0.0000280292,0.000308693,0.0003636089,0.00004759551,0.0005704944,0.008833109,0.0001105419,0.002848586,0.00002332757],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916727,0.001495772,0.0007633074,0.0002797822,0.00007451313,0.003280459,0.001161269,0.0001148609,0.00115736],"genre_scores_gemma":[0.9881087,0.00136354,0.001819307,0.0004426611,0.0001732193,0.003470612,0.00216311,0.00003586728,0.002423025],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004314214,"threshold_uncertainty_score":0.01443249,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01289863678017111,"score_gpt":0.3175022932758785,"score_spread":0.3046036564957074,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}